Drug Profile
MVA Mosaic HIV vaccine - Janssen Vaccines and Prevention
Alternative Names: Modified Vaccinia Ankara Mosaic HIV vaccine - Janssen Vaccines and Prevention; Modified vaccinia ankara mosaic vaccine-Janssen Vaccines and Prevention; MVA HIV vaccine-Janssen Vaccines and Prevention; MVA mosaic-Janssen Vaccines and Prevention; MVA-MosaicLatest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Crucell Holland
- Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 01 Mar 2022 Janssen Vaccines & Prevention B.V. completes a phase-I/II clinical trials in HIV infections (Prevention) in USA, Uganda, Thailand, South Africa, Rwanda (IM) (NCT02315703)
- 29 Sep 2021 Phase-I/II development in HIV infections (Combination therapy, Prevention) is still ongoing Uganda, USA, Rwanda, South Africa, Thailand (IM) (NCT02315703)
- 29 Sep 2021 No development reported - Phase-I/II for HIV infections (Combination therapy, Treatment-experienced) in Thailand (IM)